208 related articles for article (PubMed ID: 25984718)
21. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Drost R; Dhillon KK; van der Gulden H; van der Heijden I; Brandsma I; Cruz C; Chondronasiou D; Castroviejo-Bermejo M; Boon U; Schut E; van der Burg E; Wientjens E; Pieterse M; Klijn C; Klarenbeek S; Loayza-Puch F; Elkon R; van Deemter L; Rottenberg S; van de Ven M; Dekkers DH; Demmers JA; van Gent DC; Agami R; Balmaña J; Serra V; Taniguchi T; Bouwman P; Jonkers J
J Clin Invest; 2016 Aug; 126(8):2903-18. PubMed ID: 27454287
[TBL] [Abstract][Full Text] [Related]
22. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
[TBL] [Abstract][Full Text] [Related]
23. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
24. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the Combination of a PARP Inhibitor and UVC on Cancer Cells as Imaged by Focus Formation by the DNA Repair-related Protein 53BP1 Linked to Green Fluorescent Protein.
Tome Y; Uehara F; Miwa S; Yano S; Mii S; Efimova EV; Bouvet M; Kimura H; Tsuchiya H; Kanaya F; Hoffman RM
Anticancer Res; 2016 Aug; 36(8):3821-6. PubMed ID: 27466483
[TBL] [Abstract][Full Text] [Related]
26. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Aly A; Ganesan S
J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
[TBL] [Abstract][Full Text] [Related]
27. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
29. Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
Maxmen A
J Natl Cancer Inst; 2010 Aug; 102(15):1110-1. PubMed ID: 20668266
[No Abstract] [Full Text] [Related]
30. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
Bryant HE; Helleday T
Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
[TBL] [Abstract][Full Text] [Related]
31. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
33. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.
Fam HK; Walton C; Mitra SA; Chowdhury M; Osborne N; Choi K; Sun G; Wong PC; O'Sullivan MJ; Turashvili G; Aparicio S; Triche TJ; Bond M; Pallen CJ; Boerkoel CF
Mol Cancer Res; 2013 Oct; 11(10):1179-92. PubMed ID: 23913164
[TBL] [Abstract][Full Text] [Related]
34. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
35. Targeting the DNA repair pathway in Ewing sarcoma.
Stewart E; Goshorn R; Bradley C; Griffiths LM; Benavente C; Twarog NR; Miller GM; Caufield W; Freeman BB; Bahrami A; Pappo A; Wu J; Loh A; Karlström Å; Calabrese C; Gordon B; Tsurkan L; Hatfield MJ; Potter PM; Snyder SE; Thiagarajan S; Shirinifard A; Sablauer A; Shelat AA; Dyer MA
Cell Rep; 2014 Nov; 9(3):829-41. PubMed ID: 25437539
[TBL] [Abstract][Full Text] [Related]
36. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.
Michelena J; Lezaja A; Teloni F; Schmid T; Imhof R; Altmeyer M
Nat Commun; 2018 Jul; 9(1):2678. PubMed ID: 29992957
[TBL] [Abstract][Full Text] [Related]
37. [Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells].
Cai SY; Tang ZZ; Zeng M; Wang XJ; Lou JY; Liu C; Chen J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 May; 47(3):316-20, 336. PubMed ID: 27468472
[TBL] [Abstract][Full Text] [Related]
38. Femtosecond near-infrared laser microirradiation reveals a crucial role for PARP signaling on factor assemblies at DNA damage sites.
Saquilabon Cruz GM; Kong X; Silva BA; Khatibzadeh N; Thai R; Berns MW; Yokomori K
Nucleic Acids Res; 2016 Feb; 44(3):e27. PubMed ID: 26424850
[TBL] [Abstract][Full Text] [Related]
39. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Zhang D; Singh B; Moerland J; Mitchell O; Lockwood L; Carapellucci S; Sridhar S; Liby KT
Sci Rep; 2021 Jan; 11(1):1234. PubMed ID: 33441637
[TBL] [Abstract][Full Text] [Related]
40. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.
Liu Y; Xu H; Van der Jeught K; Li Y; Liu S; Zhang L; Fang Y; Zhang X; Radovich M; Schneider BP; He X; Huang C; Zhang C; Wan J; Ji G; Lu X
J Clin Invest; 2018 Jul; 128(7):2951-2965. PubMed ID: 29649003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
